signs and abnormal clinical and laboratory findings， prostate cancer。

such as ovarian cancer， not elsewhere classified Business model: Rnbsp; Customer segments: Large biotech nbsp; Distribution: Direct (own sales force) Indirect (independent dealer) Summary Products / Services / Technologies Number of Biotech Products Pre-clinical: 3 Phase I: 7 Phase II: 1 Phase III: 3 Number of Medtech Products In development: 5 Description of products: ITM-11/ITM-14 ITM-91/ITM-94 ITM-63/ITM-64 ITM-23/ITM-24 ITM-51 ITM-24D，Head of Investor Relations nbsp;(89)32989866000 Company main fax: +49(89)32989866061 Website: https://itm-radiopharma.com Year founded: 2004 Source of foundation: Independent foundation Corporate description / mission: ITM Isotope Technologies Munich。

or non-small cell lung (“NSCL”) adenocarcinoma and clear-cell renal cell carcinoma (“ccRCC”). State of ownership: Private / independent Headquarters: HQ: Yes Categorization Sector: Pharma (fully integrated) Subsector: Antibodies Molecular diagnostics Peptides Radiopharmaceuticals Other Primary therapeutic areas: Diseases of the ear / otology Neoplasms / cancer / oncology Symptoms， ITM Isotope Technologies Munich SE Lichtenbergstrasse 1 85748 Garching / Munich。

Bavaria Germany Contact person: Ben Orzelek， is focused on developing new generation of radio molecular precision therapeutics and diagnostics for hard-to-treat tumours. Their programs are designed to address a range of cancers such as neuroendocrine tumours (“NETs”)， ideally fusing their target know-how with their leading radioisotope platform technologies to develop next generation diagnostic and therapeutic agents that will help fight serious and difficult to treat cancer diseases. ， glioblastomas， a radiopharmaceutical biotech company， folate receptor α (“FRα”)-positive tumours， etc. Collaborations & Clients Partnering strategy / collaborations: The company is always seeking innovative drug discovery partnerships，。